Esperion Therapeutics (ESPR) Gross Profit (2019 - 2026)

Esperion Therapeutics has reported Gross Profit for 8 years, with the latest figure at $45.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 36.09% year-over-year to $45.5 million; the trailing twelve-month figure through Mar 2026 stood at $178.8 million (up 5.51% YoY), and the FY2024 full-year result was $263.7 million, up 260.92% from the prior year.
• Gross Profit for Q1 2026 stood at $45.5 million, down from $46.0 million in the prior quarter.
• The five-year high for Gross Profit was $127.7 million in Q1 2024, with the low at $9.7 million in Q2 2022.
• Historically, Gross Profit has averaged $35.3 million across 5 years, with a median of $27.1 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit plunged 75.13% — and 2024, when it soared 907.02%.
• Esperion Therapeutics' Gross Profit stood at $14.7 million in 2022, then soared by 41.89% to $20.8 million in 2023, then surged by 109.07% to $43.5 million in 2024, then increased by 5.84% to $46.0 million in 2025, then slipped by 1.06% to $45.5 million in 2026.
• The last three Gross Profit figures came in at $45.5 million (Q1 2026), $46.0 million (Q3 2025), and $53.8 million (Q2 2025), per Business Quant data.